PRTC Stock Overview Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
PureTech Health plc Competitors Price History & Performance
Summary of share price highs, lows and changes for PureTech Health Historical stock prices Current Share Price UK£1.50 52 Week High UK£2.39 52 Week Low UK£1.33 Beta 0.96 1 Month Change -0.27% 3 Month Change -3.60% 1 Year Change -21.16% 3 Year Change -42.50% 5 Year Change -50.72% Change since IPO -15.84%
Recent News & Updates
PureTech Health plc Receives Fda Fast Track Designation for Lyt-200 in Acute Myeloid Leukemia Jan 09 PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
PureTech Health plc Presents Data for LYT-200 (anti-Galectin-9 Monoclonal Antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting Dec 10
Consensus revenue estimates decrease by 78% Nov 20
PureTech Health plc Appoints Sandi Peterson to Its Board of Directors Nov 20
Is PureTech Health (LON:PRTC) Using Debt Sensibly? Nov 15 See more updates
PureTech Health plc Receives Fda Fast Track Designation for Lyt-200 in Acute Myeloid Leukemia Jan 09 PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
PureTech Health plc Presents Data for LYT-200 (anti-Galectin-9 Monoclonal Antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting Dec 10
Consensus revenue estimates decrease by 78% Nov 20
PureTech Health plc Appoints Sandi Peterson to Its Board of Directors Nov 20
Is PureTech Health (LON:PRTC) Using Debt Sensibly? Nov 15
PureTech Health plc Appoints Lauren White as Chief Financial Officer Nov 06
Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting Oct 09
PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults Sep 27
Consensus EPS estimates upgraded to US$0.55 loss Sep 24
Consensus revenue estimates decrease by 57% Sep 10
New major risk - Revenue and earnings growth Sep 09
Consensus revenue estimates increase by 973%, EPS downgraded Sep 04
First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 29
Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024 Aug 22
PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024 Aug 21
PureTech Health plc Appoints David Wheadon to Its Board of Directors Aug 14
PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors Jun 20 PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million. May 21
Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments May 08
PureTech Health plc, Annual General Meeting, Jun 13, 2024 Apr 27
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 26
PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024 Apr 19
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis Apr 16
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers Apr 12 PureTech Health plc Announces Chief Executive Officer Changes
New minor risk - Financial data availability Apr 02
New major risk - Revenue and earnings growth Feb 05
Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023 Dec 07
Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300 Nov 14
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting Oct 12
Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer Sep 27
Consensus revenue estimates fall by 88% Sep 05
First half 2023 earnings: EPS and revenues miss analyst expectations Aug 30
PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023 Aug 22
PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome Aug 02
Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders Jun 22
Full year 2022 earnings: EPS and revenues exceed analyst expectations Apr 30
Consensus EPS estimates fall by 29% Mar 24
PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression Feb 15
PureTech Health plc Announces Executive Changes Dec 22
PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300 Dec 21
PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting Dec 13
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform Dec 01 Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC). Oct 11
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 Sep 07
PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 Sep 06
Consensus forecasts updated Sep 01
What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today Aug 27
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 25
PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022 Aug 04
PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan Aug 02
PureTech Health plc Announces New Akili Data in Lupus Jul 15
Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100 Jul 01 PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)
PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications Jun 14
PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022 Jun 07
PureTech Health plc Presents Additional Phase 1 Data for LYT-100 May 17
Consensus forecasts updated May 03
Is PureTech Health (LON:PRTC) A Risky Investment? Apr 28
Full year 2021 earnings: EPS and revenues exceed analyst expectations Apr 27
PureTech Health plc, Annual General Meeting, Jun 15, 2022 Apr 26
Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results Apr 14
PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine Apr 12
PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022 Apr 07
President recently bought UK£51k worth of stock Feb 05
PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone Jan 06
President recently bought UK£73k worth of stock Dec 22
Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt? Dec 21
PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021 Dec 17
PureTech Health plc's Lymphatic Platform Candidate Human Study Dec 09
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance Sep 21
Is PureTech Health (LON:PRTC) Using Too Much Debt? Aug 28
Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS Aug 25
First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020) Aug 25
President recently bought UK£83k worth of stock Jul 24
PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202 Jul 01
President recently bought UK£69k worth of stock Jun 25
PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics. Jun 17
Puretech’s Gelesis Presents Plenity Data at American Association of Clinical Endocrinology 2021 May 28
COO, Secretary & Executive Director has left the company May 19
PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Apr 18
Full year 2020 earnings released Apr 17
PureTech Health plc Announces Executive Changes Mar 18
PureTech Health plc to Report Fiscal Year 2020 Final Results on Apr 15, 2021 Mar 15
PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release Feb 26 Shareholder Returns PRTC GB Biotechs GB Market 7D 7.0% 4.9% 1.0% 1Y -21.2% -18.1% 10.4%
See full shareholder returns
Return vs Industry: PRTC underperformed the UK Biotechs industry which returned -18.1% over the past year.
Return vs Market: PRTC underperformed the UK Market which returned 10.4% over the past year.
Price Volatility Is PRTC's price volatile compared to industry and market? PRTC volatility PRTC Average Weekly Movement 5.5% Biotechs Industry Average Movement 9.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 11.0% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: PRTC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: PRTC's weekly volatility (5%) has been stable over the past year.
About the Company PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
Show more PureTech Health plc Fundamentals Summary How do PureTech Health's earnings and revenue compare to its market cap? PRTC fundamental statistics Market cap UK£358.65m Earnings (TTM ) -UK£66.26m Revenue (TTM ) UK£376.02k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PRTC income statement (TTM ) Revenue US$468.00k Cost of Revenue US$82.02m Gross Profit -US$81.55m Other Expenses US$917.00k Earnings -US$82.47m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.34 Gross Margin -17,425.00% Net Profit Margin -17,620.94% Debt/Equity Ratio 40.7%
How did PRTC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 01:39 End of Day Share Price 2025/01/31 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources PureTech Health plc is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Welford Jefferies LLC Thomas Smith Leerink Partners LLC Faisal Khurshid Leerink Partners LLC
Show 5 more analysts 
